Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

The most important potential for ceritinib is related to the activity seen in naïve patients. Rolfo says there is a possibility to use this agent early on.

There are also new combinations with ceritinib evaluating the potential to overcome resistance. Unfortunately, even with new promising agents, there is always a possibility of recurrence through mutations or transformations.

Christian Rolfo, MD, PhD, MHBA

Articles

Dr. Rolfo Discusses the Potential Utility of Ceritinib